<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460369</url>
  </required_header>
  <id_info>
    <org_study_id>Malariallada</org_study_id>
    <nct_id>NCT00460369</nct_id>
  </id_info>
  <brief_title>Treatment of Uncomplicated Malaria in Benin</brief_title>
  <official_title>Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malaria is a life-threatening disease especially in small children. A high degree of
      Plasmodium falciparum resistance to chloroquine has already spread to South-Benin where this
      study is taking place. In the past few years, the recommendation for a first-line treatment
      in this area has moved from chloroquine to sulfadoxine-pyrimethamine (SP). There is growing
      evidence that Plasmodium falciparum resistance to SP has come to South-Benin. The aim of the
      study is to compare the efficacy of SP to two compact artemisinin-based therapies (ACT):
      artemether-lumefantrine and the amodiaquine-artesunate coformulation. ACT will be
      unsupervised.

      The primary endpoint is an effectiveness comparison (PCR corrected) at day 28. Secondary
      outcomes are effectiveness comparisons (PCR corrected) at day 14 and 42 and a study on the
      relationships between ACT PK data (day 3) and outcome.

      Expected total enrollment: 225 patients

      Study start: April 2007; expected completion: December 2007
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>effectiveness comparisons (PCR corrected)</measure>
    <time_frame>day 14 and day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse events</measure>
    <time_frame>day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Uncomplicated Malaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sulfadoxine-pyrimethamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>artemether-lumefantrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amodiaquine-artesunate coformulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulfadoxine-pyrimethamine</intervention_name>
    <description>tablets 1,25/25 mg
1 tablet per 20 kg of body weight Single drug intake</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Fansidar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artemether-lumefantrine</intervention_name>
    <description>tablets 20/120 mg
1 tablet twice daily for 3 days below 15 kg of bodyweight
2 tablets twice daily for 3 days below 24 kg of bodyweight
3 tablets twice daily for 3 days below 35 kg of bodyweight</description>
    <arm_group_label>2</arm_group_label>
    <other_name>coartem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amodiaquine-artesunate coformulation</intervention_name>
    <description>one 25mg/67,5mg tablet, once daily for 3 days below 9 kg
one 50/135mg tablet, once daily for 3 days below 18 kg</description>
    <arm_group_label>3</arm_group_label>
    <other_name>coarsucam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6-119 months old

          -  fever or history of fever of less than 24 hours

          -  p falciparum parasitemia &gt; 1000 trophozoïtes/µL

          -  informed consent signed

        Exclusion Criteria:

          -  &lt; 5 kg

          -  danger or severity signs of malaria

          -  known underlying chronic disease

          -  Hb &lt; 5g/dL

          -  adequate malaria treatment taken within 3 days before visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>119 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François Faucher, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de recherche pour le développement UR010</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Deloron, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut de Recherche pour le Développement UR010</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de santé</name>
      <address>
        <city>Allada</city>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Benin</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <last_update_submitted>April 11, 2008</last_update_submitted>
  <last_update_submitted_qc>April 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Faucher</name_title>
    <organization>Institut de Recherche pour le Développement</organization>
  </responsible_party>
  <keyword>uncomplicated malaria</keyword>
  <keyword>children</keyword>
  <keyword>treatment</keyword>
  <keyword>effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

